热门资讯> 正文
周日报道，Arcus ARC-20数据显示，卡斯达蒂凡和卡博替尼在接受免疫治疗的肾脏癌中的确诊有效率为46%
2025-06-02 14:52
- Treatment with casdatifan, a HIF-2a inhibitor, plus cabozantinib, a tyrosine kinase inhibitor, showed a confirmed overall response rate (ORR) of 46% in patients who reached a minimum of 12 weeks (two scans) of follow-up
- The combination had a manageable safety profile, and there was no meaningful overlapping toxicity for the two drugs
- These data support the initiation of PEAK-1, a Phase 3 study that will evaluate casdatifan plus cabozantinib in immunotherapy-experienced clear cell renal cell carcinoma (ccRCC) patients, and eVOLVE-RCC02, a Phase 1b/3 study in first-line ccRCC patients, both of which will begin shortly
- Arcus will host a conference call to discuss these data at 5:00 AM PT / 7:00 AM CT on Monday, June 2, 2025
推荐文章
风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。
